Peng, S., Zhang, Y., Lin, X., Si, C., Horn, R. D. V., Dempsey, J. A., Goetz, E., Evans, R. J., Farber, A., Vandekopple, M. J., Ming, W., Gao, H., Yu, C., Xu, W. G., Brown, N. E., Dowless, M. S., Pulliam, N., Barda, D. A., Guo, D., Boulet, S. L., Huber, L., Capen, A., Jones, B., Bogner, S., Castanares, M. A., Stephens, J. R., Johnson, M. A., Curtis, C. L., Strelow, J. M., Xiao, J., Ballard, J., Bocchinfuso, W. P., Chalmers, M. J., Wang, J., Hendle, J., Saflor, M. D., Lagutan, D. M., Gheyi, T., Sarkar, A., Kearins, M., Tung, F., Ho, J., Rodgers, L., Benach, J., Frommelt, A. J., Zhou, L., Ackermann, B. L., McCann, D., Klippel, A., Buchanan, S. G., Henry, J. R., Gong, X. (2026). Characterization of KRASG12C inhibitor olomorasib single-agent and combination with activity in KRASG12C-mutant models. Nature Communications. https://doi.org/10.1038/s41467-026-72650-y